nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CYP1A2—chronic obstructive pulmonary disease	0.26	1	CbGaD
Sorafenib—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0273	0.0865	CbGbCtD
Sorafenib—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0273	0.0865	CbGbCtD
Sorafenib—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0247	0.0781	CbGbCtD
Sorafenib—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0227	0.0719	CbGbCtD
Sorafenib—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0227	0.0719	CbGbCtD
Sorafenib—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0215	0.0679	CbGbCtD
Sorafenib—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0208	0.0658	CbGbCtD
Sorafenib—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0208	0.0658	CbGbCtD
Sorafenib—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0185	0.0586	CbGbCtD
Sorafenib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0174	0.0552	CbGbCtD
Sorafenib—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0172	0.0545	CbGbCtD
Sorafenib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0118	0.0373	CbGbCtD
Sorafenib—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0115	0.0363	CbGbCtD
Sorafenib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0112	0.0356	CbGbCtD
Sorafenib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.01	0.0317	CbGbCtD
Sorafenib—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00981	0.031	CbGbCtD
Sorafenib—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00926	0.0293	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00588	0.0186	CbGbCtD
Sorafenib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00555	0.0176	CbGbCtD
Sorafenib—MAPK15—bronchus—chronic obstructive pulmonary disease	0.00315	0.0325	CbGeAlD
Sorafenib—CDK7—respiratory system—chronic obstructive pulmonary disease	0.00223	0.023	CbGeAlD
Sorafenib—CDK7—connective tissue—chronic obstructive pulmonary disease	0.00197	0.0203	CbGeAlD
Sorafenib—ZAK—respiratory system—chronic obstructive pulmonary disease	0.00193	0.0199	CbGeAlD
Sorafenib—MAP3K19—respiratory system—chronic obstructive pulmonary disease	0.00185	0.0191	CbGeAlD
Sorafenib—TIE1—respiratory system—chronic obstructive pulmonary disease	0.00177	0.0182	CbGeAlD
Sorafenib—HIPK3—connective tissue—chronic obstructive pulmonary disease	0.00166	0.0172	CbGeAlD
Sorafenib—FLT3—respiratory system—chronic obstructive pulmonary disease	0.00161	0.0166	CbGeAlD
Sorafenib—ZAK—bronchus—chronic obstructive pulmonary disease	0.00159	0.0164	CbGeAlD
Sorafenib—HIPK3—bronchus—chronic obstructive pulmonary disease	0.00156	0.016	CbGeAlD
Sorafenib—FLT4—respiratory system—chronic obstructive pulmonary disease	0.00146	0.0151	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00142	0.0147	CbGeAlD
Sorafenib—FLT3—connective tissue—chronic obstructive pulmonary disease	0.00141	0.0146	CbGeAlD
Sorafenib—MKNK2—respiratory system—chronic obstructive pulmonary disease	0.00132	0.0136	CbGeAlD
Sorafenib—RALBP1—respiratory system—chronic obstructive pulmonary disease	0.00119	0.0123	CbGeAlD
Sorafenib—CDK7—lung—chronic obstructive pulmonary disease	0.00119	0.0122	CbGeAlD
Sorafenib—FGFR1—bronchus—chronic obstructive pulmonary disease	0.00118	0.0122	CbGeAlD
Sorafenib—TAOK2—lung—chronic obstructive pulmonary disease	0.00118	0.0121	CbGeAlD
Sorafenib—MKNK2—connective tissue—chronic obstructive pulmonary disease	0.00116	0.012	CbGeAlD
Sorafenib—FLT1—respiratory system—chronic obstructive pulmonary disease	0.00113	0.0117	CbGeAlD
Sorafenib—RET—connective tissue—chronic obstructive pulmonary disease	0.00113	0.0117	CbGeAlD
Sorafenib—RAF1—respiratory system—chronic obstructive pulmonary disease	0.00113	0.0116	CbGeAlD
Sorafenib—MAP3K7—bronchus—chronic obstructive pulmonary disease	0.00112	0.0116	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—chronic obstructive pulmonary disease	0.0011	0.0113	CbGeAlD
Sorafenib—MKNK2—bronchus—chronic obstructive pulmonary disease	0.00109	0.0112	CbGeAlD
Sorafenib—STK10—respiratory system—chronic obstructive pulmonary disease	0.00107	0.0111	CbGeAlD
Sorafenib—MKNK1—bronchus—chronic obstructive pulmonary disease	0.00107	0.0111	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00106	0.011	CbGeAlD
Sorafenib—PDGFRA—respiratory system—chronic obstructive pulmonary disease	0.00106	0.011	CbGeAlD
Sorafenib—ZAK—lung—chronic obstructive pulmonary disease	0.00103	0.0106	CbGeAlD
Sorafenib—MAP3K7—trachea—chronic obstructive pulmonary disease	0.00101	0.0104	CbGeAlD
Sorafenib—HIPK3—lung—chronic obstructive pulmonary disease	0.001	0.0103	CbGeAlD
Sorafenib—FLT1—connective tissue—chronic obstructive pulmonary disease	0.000999	0.0103	CbGeAlD
Sorafenib—RAF1—connective tissue—chronic obstructive pulmonary disease	0.000993	0.0102	CbGeAlD
Sorafenib—MAP3K19—lung—chronic obstructive pulmonary disease	0.000983	0.0101	CbGeAlD
Sorafenib—RALBP1—bronchus—chronic obstructive pulmonary disease	0.000982	0.0101	CbGeAlD
Sorafenib—MKNK2—trachea—chronic obstructive pulmonary disease	0.000976	0.0101	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000961	0.00991	CbGeAlD
Sorafenib—KDR—respiratory system—chronic obstructive pulmonary disease	0.000959	0.00989	CbGeAlD
Sorafenib—TIE1—lung—chronic obstructive pulmonary disease	0.000938	0.00967	CbGeAlD
Sorafenib—CSF1R—respiratory system—chronic obstructive pulmonary disease	0.000936	0.00965	CbGeAlD
Sorafenib—PDGFRA—connective tissue—chronic obstructive pulmonary disease	0.000936	0.00965	CbGeAlD
Sorafenib—FLT1—bronchus—chronic obstructive pulmonary disease	0.000934	0.00963	CbGeAlD
Sorafenib—RAF1—bronchus—chronic obstructive pulmonary disease	0.000928	0.00957	CbGeAlD
Sorafenib—EPHB6—bronchus—chronic obstructive pulmonary disease	0.000923	0.00952	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000914	0.00942	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000908	0.00937	CbGeAlD
Sorafenib—BRAF—lung—chronic obstructive pulmonary disease	0.000899	0.00927	CbGeAlD
Sorafenib—STK10—bronchus—chronic obstructive pulmonary disease	0.000884	0.00912	CbGeAlD
Sorafenib—RALBP1—trachea—chronic obstructive pulmonary disease	0.000882	0.00909	CbGeAlD
Sorafenib—EPHX2—lung—chronic obstructive pulmonary disease	0.000859	0.00886	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—chronic obstructive pulmonary disease	0.000856	0.00883	CbGeAlD
Sorafenib—FLT3—lung—chronic obstructive pulmonary disease	0.000853	0.0088	CbGeAlD
Sorafenib—KIT—respiratory system—chronic obstructive pulmonary disease	0.00085	0.00877	CbGeAlD
Sorafenib—KDR—connective tissue—chronic obstructive pulmonary disease	0.000844	0.00871	CbGeAlD
Sorafenib—FLT1—trachea—chronic obstructive pulmonary disease	0.000838	0.00865	CbGeAlD
Sorafenib—RAF1—trachea—chronic obstructive pulmonary disease	0.000834	0.0086	CbGeAlD
Sorafenib—PDGFRB—respiratory system—chronic obstructive pulmonary disease	0.00083	0.00856	CbGeAlD
Sorafenib—EPHB6—trachea—chronic obstructive pulmonary disease	0.000829	0.00855	CbGeAlD
Sorafenib—CSF1R—connective tissue—chronic obstructive pulmonary disease	0.000824	0.0085	CbGeAlD
Sorafenib—MAP2K5—bronchus—chronic obstructive pulmonary disease	0.000789	0.00814	CbGeAlD
Sorafenib—KDR—bronchus—chronic obstructive pulmonary disease	0.000789	0.00814	CbGeAlD
Sorafenib—PDGFRA—trachea—chronic obstructive pulmonary disease	0.000786	0.0081	CbGeAlD
Sorafenib—FLT4—lung—chronic obstructive pulmonary disease	0.000775	0.00799	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—chronic obstructive pulmonary disease	0.000772	0.00797	CbGeAlD
Sorafenib—CSF1R—bronchus—chronic obstructive pulmonary disease	0.00077	0.00795	CbGeAlD
Sorafenib—FGFR1—lung—chronic obstructive pulmonary disease	0.000764	0.00788	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—chronic obstructive pulmonary disease	0.000754	0.00777	CbGeAlD
Sorafenib—KIT—connective tissue—chronic obstructive pulmonary disease	0.000748	0.00772	CbGeAlD
Sorafenib—PDGFRB—connective tissue—chronic obstructive pulmonary disease	0.000731	0.00754	CbGeAlD
Sorafenib—MAP3K7—lung—chronic obstructive pulmonary disease	0.000724	0.00746	CbGeAlD
Sorafenib—MAP2K5—trachea—chronic obstructive pulmonary disease	0.000709	0.00731	CbGeAlD
Sorafenib—KDR—trachea—chronic obstructive pulmonary disease	0.000709	0.00731	CbGeAlD
Sorafenib—MKNK2—lung—chronic obstructive pulmonary disease	0.000701	0.00723	CbGeAlD
Sorafenib—KIT—bronchus—chronic obstructive pulmonary disease	0.0007	0.00721	CbGeAlD
Sorafenib—MKNK1—lung—chronic obstructive pulmonary disease	0.000693	0.00714	CbGeAlD
Sorafenib—CSF1R—trachea—chronic obstructive pulmonary disease	0.000692	0.00713	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—chronic obstructive pulmonary disease	0.000684	0.00706	CbGeAlD
Sorafenib—PDGFRB—bronchus—chronic obstructive pulmonary disease	0.000683	0.00705	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—chronic obstructive pulmonary disease	0.000668	0.00689	CbGeAlD
Sorafenib—RALBP1—lung—chronic obstructive pulmonary disease	0.000633	0.00653	CbGeAlD
Sorafenib—KIT—trachea—chronic obstructive pulmonary disease	0.000628	0.00648	CbGeAlD
Sorafenib—PDGFRB—trachea—chronic obstructive pulmonary disease	0.000613	0.00633	CbGeAlD
Sorafenib—FLT1—lung—chronic obstructive pulmonary disease	0.000602	0.00621	CbGeAlD
Sorafenib—RAF1—lung—chronic obstructive pulmonary disease	0.000599	0.00618	CbGeAlD
Sorafenib—EPHB6—lung—chronic obstructive pulmonary disease	0.000596	0.00614	CbGeAlD
Sorafenib—STK10—lung—chronic obstructive pulmonary disease	0.00057	0.00588	CbGeAlD
Sorafenib—PDGFRA—lung—chronic obstructive pulmonary disease	0.000565	0.00582	CbGeAlD
Sorafenib—ABCC4—bronchus—chronic obstructive pulmonary disease	0.000544	0.00561	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—chronic obstructive pulmonary disease	0.000529	0.00546	CbGeAlD
Sorafenib—MAP2K5—lung—chronic obstructive pulmonary disease	0.000509	0.00525	CbGeAlD
Sorafenib—KDR—lung—chronic obstructive pulmonary disease	0.000509	0.00525	CbGeAlD
Sorafenib—CSF1R—lung—chronic obstructive pulmonary disease	0.000497	0.00513	CbGeAlD
Sorafenib—KIT—lung—chronic obstructive pulmonary disease	0.000451	0.00465	CbGeAlD
Sorafenib—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000449	0.00463	CbGeAlD
Sorafenib—PDGFRB—lung—chronic obstructive pulmonary disease	0.000441	0.00455	CbGeAlD
Sorafenib—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000433	0.00447	CbGeAlD
Sorafenib—CYP2B6—respiratory system—chronic obstructive pulmonary disease	0.00043	0.00444	CbGeAlD
Sorafenib—Vismodegib—ALB—chronic obstructive pulmonary disease	0.000383	1	CrCbGaD
Sorafenib—CYP2B6—bronchus—chronic obstructive pulmonary disease	0.000354	0.00365	CbGeAlD
Sorafenib—ABCC4—lung—chronic obstructive pulmonary disease	0.000351	0.00362	CbGeAlD
Sorafenib—HTR2B—lung—chronic obstructive pulmonary disease	0.000349	0.0036	CbGeAlD
Sorafenib—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000303	0.00189	CcSEcCtD
Sorafenib—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000303	0.00189	CcSEcCtD
Sorafenib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000301	0.00188	CcSEcCtD
Sorafenib—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.00187	CcSEcCtD
Sorafenib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000298	0.00186	CcSEcCtD
Sorafenib—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000298	0.00186	CcSEcCtD
Sorafenib—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000297	0.00185	CcSEcCtD
Sorafenib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000294	0.00184	CcSEcCtD
Sorafenib—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000292	0.00182	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000291	0.00181	CcSEcCtD
Sorafenib—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000288	0.0018	CcSEcCtD
Sorafenib—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.0018	CcSEcCtD
Sorafenib—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000287	0.00179	CcSEcCtD
Sorafenib—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00176	CcSEcCtD
Sorafenib—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000281	0.00175	CcSEcCtD
Sorafenib—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000277	0.00173	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000276	0.00172	CcSEcCtD
Sorafenib—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000275	0.00172	CcSEcCtD
Sorafenib—Cough—Formoterol—chronic obstructive pulmonary disease	0.000275	0.00172	CcSEcCtD
Sorafenib—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000273	0.0017	CcSEcCtD
Sorafenib—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.0017	CcSEcCtD
Sorafenib—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000272	0.0017	CcSEcCtD
Sorafenib—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.0017	CcSEcCtD
Sorafenib—Skin exfoliation—Prednisone—chronic obstructive pulmonary disease	0.000271	0.00169	CcSEcCtD
Sorafenib—Cough—Montelukast—chronic obstructive pulmonary disease	0.00027	0.00168	CcSEcCtD
Sorafenib—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.000269	0.00168	CcSEcCtD
Sorafenib—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000269	0.00168	CcSEcCtD
Sorafenib—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00168	CcSEcCtD
Sorafenib—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00168	CcSEcCtD
Sorafenib—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00168	CcSEcCtD
Sorafenib—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00168	CcSEcCtD
Sorafenib—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000268	0.00167	CcSEcCtD
Sorafenib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000268	0.00167	CcSEcCtD
Sorafenib—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00167	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00166	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00166	CcSEcCtD
Sorafenib—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000267	0.00166	CcSEcCtD
Sorafenib—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000263	0.00164	CcSEcCtD
Sorafenib—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000263	0.00164	CcSEcCtD
Sorafenib—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000263	0.00164	CcSEcCtD
Sorafenib—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000263	0.00164	CcSEcCtD
Sorafenib—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00163	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000261	0.00163	CcSEcCtD
Sorafenib—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000261	0.00163	CcSEcCtD
Sorafenib—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.00026	0.00162	CcSEcCtD
Sorafenib—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00162	CcSEcCtD
Sorafenib—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000258	0.00161	CcSEcCtD
Sorafenib—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000258	0.00161	CcSEcCtD
Sorafenib—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000257	0.0016	CcSEcCtD
Sorafenib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000256	0.0016	CcSEcCtD
Sorafenib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000256	0.0016	CcSEcCtD
Sorafenib—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.00158	CcSEcCtD
Sorafenib—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.00158	CcSEcCtD
Sorafenib—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000254	0.00158	CcSEcCtD
Sorafenib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.00158	CcSEcCtD
Sorafenib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000253	0.00158	CcSEcCtD
Sorafenib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000252	0.00157	CcSEcCtD
Sorafenib—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000252	0.00157	CcSEcCtD
Sorafenib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000251	0.00156	CcSEcCtD
Sorafenib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00156	CcSEcCtD
Sorafenib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00156	CcSEcCtD
Sorafenib—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000249	0.00156	CcSEcCtD
Sorafenib—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00155	CcSEcCtD
Sorafenib—ABCG2—lung—chronic obstructive pulmonary disease	0.000248	0.00256	CbGeAlD
Sorafenib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000247	0.00154	CcSEcCtD
Sorafenib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000247	0.00154	CcSEcCtD
Sorafenib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000245	0.00153	CcSEcCtD
Sorafenib—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000243	0.00152	CcSEcCtD
Sorafenib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00151	CcSEcCtD
Sorafenib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000241	0.0015	CcSEcCtD
Sorafenib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000239	0.00149	CcSEcCtD
Sorafenib—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00149	CcSEcCtD
Sorafenib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00149	CcSEcCtD
Sorafenib—CYP1A2—lung—chronic obstructive pulmonary disease	0.000238	0.00246	CbGeAlD
Sorafenib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00147	CcSEcCtD
Sorafenib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000235	0.00147	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00146	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00146	CcSEcCtD
Sorafenib—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.00145	CcSEcCtD
Sorafenib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000232	0.00144	CcSEcCtD
Sorafenib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.00023	0.00237	CbGeAlD
Sorafenib—CYP3A5—lung—chronic obstructive pulmonary disease	0.00023	0.00237	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00143	CcSEcCtD
Sorafenib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.00143	CcSEcCtD
Sorafenib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00023	0.00143	CcSEcCtD
Sorafenib—CYP2B6—lung—chronic obstructive pulmonary disease	0.000229	0.00236	CbGeAlD
Sorafenib—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000227	0.00142	CcSEcCtD
Sorafenib—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00141	CcSEcCtD
Sorafenib—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00141	CcSEcCtD
Sorafenib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000226	0.00141	CcSEcCtD
Sorafenib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.0014	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000222	0.00139	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000222	0.00139	CcSEcCtD
Sorafenib—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00139	CcSEcCtD
Sorafenib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000222	0.00139	CcSEcCtD
Sorafenib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000222	0.00139	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00138	CcSEcCtD
Sorafenib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00137	CcSEcCtD
Sorafenib—Pain—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00137	CcSEcCtD
Sorafenib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00137	CcSEcCtD
Sorafenib—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00137	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000218	0.00136	CcSEcCtD
Sorafenib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000218	0.00136	CcSEcCtD
Sorafenib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00135	CcSEcCtD
Sorafenib—Pain—Montelukast—chronic obstructive pulmonary disease	0.000216	0.00135	CcSEcCtD
Sorafenib—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000216	0.00135	CcSEcCtD
Sorafenib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000215	0.00134	CcSEcCtD
Sorafenib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000214	0.00134	CcSEcCtD
Sorafenib—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000214	0.00134	CcSEcCtD
Sorafenib—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00134	CcSEcCtD
Sorafenib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000213	0.00133	CcSEcCtD
Sorafenib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000213	0.00133	CcSEcCtD
Sorafenib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000212	0.00132	CcSEcCtD
Sorafenib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00132	CcSEcCtD
Sorafenib—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000211	0.00132	CcSEcCtD
Sorafenib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.00132	CcSEcCtD
Sorafenib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.00131	CcSEcCtD
Sorafenib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000211	0.00131	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.00131	CcSEcCtD
Sorafenib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.00131	CcSEcCtD
Sorafenib—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.0013	CcSEcCtD
Sorafenib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.0013	CcSEcCtD
Sorafenib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000206	0.00129	CcSEcCtD
Sorafenib—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00128	CcSEcCtD
Sorafenib—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00128	CcSEcCtD
Sorafenib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.00127	CcSEcCtD
Sorafenib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000204	0.00127	CcSEcCtD
Sorafenib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000204	0.00127	CcSEcCtD
Sorafenib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.00127	CcSEcCtD
Sorafenib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000203	0.00127	CcSEcCtD
Sorafenib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000201	0.00126	CcSEcCtD
Sorafenib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000201	0.00125	CcSEcCtD
Sorafenib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000201	0.00125	CcSEcCtD
Sorafenib—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.0002	0.00125	CcSEcCtD
Sorafenib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.0002	0.00125	CcSEcCtD
Sorafenib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00124	CcSEcCtD
Sorafenib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00124	CcSEcCtD
Sorafenib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00124	CcSEcCtD
Sorafenib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00123	CcSEcCtD
Sorafenib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000196	0.00122	CcSEcCtD
Sorafenib—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000195	0.00122	CcSEcCtD
Sorafenib—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00121	CcSEcCtD
Sorafenib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.0012	CcSEcCtD
Sorafenib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.0012	CcSEcCtD
Sorafenib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00118	CcSEcCtD
Sorafenib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00118	CcSEcCtD
Sorafenib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00019	0.00118	CcSEcCtD
Sorafenib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000189	0.00118	CcSEcCtD
Sorafenib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000188	0.00117	CcSEcCtD
Sorafenib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000186	0.00116	CcSEcCtD
Sorafenib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000185	0.00115	CcSEcCtD
Sorafenib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000185	0.00115	CcSEcCtD
Sorafenib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000182	0.00114	CcSEcCtD
Sorafenib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000182	0.00114	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000182	0.00113	CcSEcCtD
Sorafenib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000181	0.00113	CcSEcCtD
Sorafenib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00112	CcSEcCtD
Sorafenib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000178	0.00111	CcSEcCtD
Sorafenib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000176	0.0011	CcSEcCtD
Sorafenib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.0011	CcSEcCtD
Sorafenib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000175	0.00109	CcSEcCtD
Sorafenib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000175	0.00109	CcSEcCtD
Sorafenib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00109	CcSEcCtD
Sorafenib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000173	0.00108	CcSEcCtD
Sorafenib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00107	CcSEcCtD
Sorafenib—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.00107	CcSEcCtD
Sorafenib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00106	CcSEcCtD
Sorafenib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00106	CcSEcCtD
Sorafenib—ABCB1—trachea—chronic obstructive pulmonary disease	0.00017	0.00175	CbGeAlD
Sorafenib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00104	CcSEcCtD
Sorafenib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000167	0.00104	CcSEcCtD
Sorafenib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.00104	CcSEcCtD
Sorafenib—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000164	0.00102	CcSEcCtD
Sorafenib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000164	0.00102	CcSEcCtD
Sorafenib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000164	0.00102	CcSEcCtD
Sorafenib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00101	CcSEcCtD
Sorafenib—Rash—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00101	CcSEcCtD
Sorafenib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00101	CcSEcCtD
Sorafenib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00101	CcSEcCtD
Sorafenib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00101	CcSEcCtD
Sorafenib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00101	CcSEcCtD
Sorafenib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000161	0.00101	CcSEcCtD
Sorafenib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.001	CcSEcCtD
Sorafenib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00016	0.001	CcSEcCtD
Sorafenib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000159	0.000992	CcSEcCtD
Sorafenib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000159	0.000991	CcSEcCtD
Sorafenib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000158	0.000986	CcSEcCtD
Sorafenib—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000157	0.000977	CcSEcCtD
Sorafenib—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.000974	CcSEcCtD
Sorafenib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000972	CcSEcCtD
Sorafenib—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000972	CcSEcCtD
Sorafenib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.000965	CcSEcCtD
Sorafenib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000957	CcSEcCtD
Sorafenib—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000153	0.000956	CcSEcCtD
Sorafenib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000956	CcSEcCtD
Sorafenib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000153	0.000954	CcSEcCtD
Sorafenib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.000954	CcSEcCtD
Sorafenib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00095	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.00015	0.000937	CcSEcCtD
Sorafenib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00015	0.000935	CcSEcCtD
Sorafenib—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000921	CcSEcCtD
Sorafenib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000901	CcSEcCtD
Sorafenib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000895	CcSEcCtD
Sorafenib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00089	CcSEcCtD
Sorafenib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000875	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000139	0.00087	CcSEcCtD
Sorafenib—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.000856	CcSEcCtD
Sorafenib—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000826	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000808	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000804	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000795	CcSEcCtD
Sorafenib—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000787	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000125	0.00078	CcSEcCtD
Sorafenib—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000775	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000775	CcSEcCtD
Sorafenib—ABCB1—lung—chronic obstructive pulmonary disease	0.000122	0.00126	CbGeAlD
Sorafenib—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.000744	CcSEcCtD
Sorafenib—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000716	CcSEcCtD
Sorafenib—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000708	CcSEcCtD
Sorafenib—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000695	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.000691	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000681	CcSEcCtD
Sorafenib—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000669	CcSEcCtD
Sorafenib—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00066	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00066	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000655	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000641	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000632	CcSEcCtD
Sorafenib—Infection—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000628	CcSEcCtD
Sorafenib—Shock—Prednisone—chronic obstructive pulmonary disease	9.97e-05	0.000622	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	9.94e-05	0.00062	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	9.85e-05	0.000614	CcSEcCtD
Sorafenib—Anorexia—Prednisone—chronic obstructive pulmonary disease	9.66e-05	0.000603	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.24e-05	0.000576	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.22e-05	0.000575	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	8.92e-05	0.000557	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.81e-05	0.00055	CcSEcCtD
Sorafenib—Rash—Prednisolone—chronic obstructive pulmonary disease	8.8e-05	0.000549	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.79e-05	0.000548	CcSEcCtD
Sorafenib—Fatigue—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000545	CcSEcCtD
Sorafenib—Headache—Prednisolone—chronic obstructive pulmonary disease	8.74e-05	0.000545	CcSEcCtD
Sorafenib—Constipation—Prednisone—chronic obstructive pulmonary disease	8.67e-05	0.000541	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.29e-05	0.000517	CcSEcCtD
Sorafenib—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.29e-05	0.000517	CcSEcCtD
Sorafenib—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.05e-05	0.000502	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.01e-05	0.0005	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.01e-05	0.0005	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.47e-05	0.000466	CcSEcCtD
Sorafenib—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.27e-05	0.000454	CcSEcCtD
Sorafenib—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.17e-05	0.000447	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6.94e-05	0.000433	CcSEcCtD
Sorafenib—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.7e-05	0.000418	CcSEcCtD
Sorafenib—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.45e-05	0.000402	CcSEcCtD
Sorafenib—Rash—Prednisone—chronic obstructive pulmonary disease	6.39e-05	0.000399	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.39e-05	0.000398	CcSEcCtD
Sorafenib—Headache—Prednisone—chronic obstructive pulmonary disease	6.35e-05	0.000396	CcSEcCtD
Sorafenib—Nausea—Prednisone—chronic obstructive pulmonary disease	6.02e-05	0.000376	CcSEcCtD
Sorafenib—PDGFRB—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.96e-06	3.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—SERPINE1—chronic obstructive pulmonary disease	5.95e-06	3.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.94e-06	3.57e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	5.92e-06	3.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—chronic obstructive pulmonary disease	5.91e-06	3.55e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—chronic obstructive pulmonary disease	5.88e-06	3.54e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.86e-06	3.52e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EGFR—chronic obstructive pulmonary disease	5.83e-06	3.5e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.81e-06	3.49e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	5.79e-06	3.48e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.75e-06	3.46e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.72e-06	3.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.72e-06	3.44e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.69e-06	3.42e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS3—chronic obstructive pulmonary disease	5.69e-06	3.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	5.68e-06	3.42e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—chronic obstructive pulmonary disease	5.65e-06	3.4e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	5.65e-06	3.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.64e-06	3.39e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.62e-06	3.38e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.56e-06	3.34e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.53e-06	3.32e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.49e-06	3.3e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.49e-06	3.3e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.46e-06	3.28e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—chronic obstructive pulmonary disease	5.43e-06	3.27e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.42e-06	3.26e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.4e-06	3.25e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.39e-06	3.24e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.37e-06	3.23e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.34e-06	3.21e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EGFR—chronic obstructive pulmonary disease	5.33e-06	3.2e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	5.33e-06	3.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.31e-06	3.2e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.3e-06	3.19e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	5.29e-06	3.18e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	5.28e-06	3.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—chronic obstructive pulmonary disease	5.27e-06	3.17e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.25e-06	3.16e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EGFR—chronic obstructive pulmonary disease	5.25e-06	3.16e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EGFR—chronic obstructive pulmonary disease	5.25e-06	3.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—chronic obstructive pulmonary disease	5.24e-06	3.15e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.24e-06	3.15e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.24e-06	3.15e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.21e-06	3.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.19e-06	3.12e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.18e-06	3.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.16e-06	3.1e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	5.16e-06	3.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.15e-06	3.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.13e-06	3.08e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—chronic obstructive pulmonary disease	5.12e-06	3.08e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—chronic obstructive pulmonary disease	5.12e-06	3.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.1e-06	3.07e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.06e-06	3.04e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.01e-06	3.01e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.99e-06	3e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EGFR—chronic obstructive pulmonary disease	4.98e-06	3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EGFR—chronic obstructive pulmonary disease	4.97e-06	2.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.97e-06	2.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.96e-06	2.98e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—chronic obstructive pulmonary disease	4.95e-06	2.97e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.94e-06	2.97e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.93e-06	2.97e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.92e-06	2.96e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.89e-06	2.94e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—chronic obstructive pulmonary disease	4.89e-06	2.94e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.87e-06	2.93e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.87e-06	2.93e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	4.86e-06	2.92e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—chronic obstructive pulmonary disease	4.85e-06	2.92e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.83e-06	2.9e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	4.82e-06	2.9e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.75e-06	2.86e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—chronic obstructive pulmonary disease	4.69e-06	2.82e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.68e-06	2.82e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—chronic obstructive pulmonary disease	4.68e-06	2.82e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.68e-06	2.81e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.68e-06	2.81e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.66e-06	2.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.65e-06	2.79e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.65e-06	2.79e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.62e-06	2.78e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—chronic obstructive pulmonary disease	4.6e-06	2.77e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—chronic obstructive pulmonary disease	4.59e-06	2.76e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.59e-06	2.76e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.58e-06	2.76e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.58e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.57e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.55e-06	2.74e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	4.51e-06	2.71e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.49e-06	2.7e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.49e-06	2.7e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—chronic obstructive pulmonary disease	4.48e-06	2.69e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.48e-06	2.69e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—chronic obstructive pulmonary disease	4.48e-06	2.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.47e-06	2.69e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.47e-06	2.69e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.46e-06	2.68e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.44e-06	2.67e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.41e-06	2.65e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.4e-06	2.65e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.38e-06	2.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.37e-06	2.63e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	4.34e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	4.3e-06	2.59e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.26e-06	2.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—chronic obstructive pulmonary disease	4.22e-06	2.54e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.21e-06	2.53e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.2e-06	2.53e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.2e-06	2.53e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.18e-06	2.52e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.18e-06	2.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.17e-06	2.51e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.15e-06	2.5e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.15e-06	2.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—chronic obstructive pulmonary disease	4.14e-06	2.49e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	4.12e-06	2.48e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	4.12e-06	2.48e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—chronic obstructive pulmonary disease	4.09e-06	2.46e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.06e-06	2.44e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—chronic obstructive pulmonary disease	4.04e-06	2.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—chronic obstructive pulmonary disease	4.04e-06	2.43e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.01e-06	2.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—chronic obstructive pulmonary disease	3.99e-06	2.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.99e-06	2.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.98e-06	2.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.98e-06	2.39e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.96e-06	2.38e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.96e-06	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.96e-06	2.38e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.91e-06	2.35e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.84e-06	2.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—chronic obstructive pulmonary disease	3.83e-06	2.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—chronic obstructive pulmonary disease	3.82e-06	2.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.81e-06	2.29e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.78e-06	2.27e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.77e-06	2.27e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.77e-06	2.27e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.77e-06	2.27e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.77e-06	2.27e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.77e-06	2.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—chronic obstructive pulmonary disease	3.76e-06	2.26e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.74e-06	2.25e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.73e-06	2.24e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.73e-06	2.24e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—chronic obstructive pulmonary disease	3.73e-06	2.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.7e-06	2.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—chronic obstructive pulmonary disease	3.69e-06	2.22e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.68e-06	2.22e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.68e-06	2.21e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.65e-06	2.2e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.64e-06	2.19e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.6e-06	2.16e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.59e-06	2.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.58e-06	2.16e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.58e-06	2.15e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.57e-06	2.15e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.54e-06	2.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—chronic obstructive pulmonary disease	3.54e-06	2.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.53e-06	2.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—chronic obstructive pulmonary disease	3.53e-06	2.12e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.52e-06	2.12e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.48e-06	2.09e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.46e-06	2.08e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.46e-06	2.08e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.45e-06	2.08e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.45e-06	2.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—chronic obstructive pulmonary disease	3.44e-06	2.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.44e-06	2.07e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.43e-06	2.06e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.42e-06	2.06e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.4e-06	2.05e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.4e-06	2.04e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.4e-06	2.04e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.37e-06	2.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.36e-06	2.02e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.29e-06	1.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.28e-06	1.97e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.25e-06	1.96e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.23e-06	1.94e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.22e-06	1.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.22e-06	1.94e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.21e-06	1.93e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.19e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	3.18e-06	1.91e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—chronic obstructive pulmonary disease	3.18e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.18e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.16e-06	1.9e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.16e-06	1.9e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.13e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.12e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	3.11e-06	1.87e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.07e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—chronic obstructive pulmonary disease	3.07e-06	1.85e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.05e-06	1.83e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.04e-06	1.83e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	2.98e-06	1.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.95e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.93e-06	1.76e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.91e-06	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.9e-06	1.74e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.9e-06	1.74e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.89e-06	1.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.87e-06	1.73e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.87e-06	1.72e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.85e-06	1.71e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.85e-06	1.71e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—chronic obstructive pulmonary disease	2.83e-06	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.82e-06	1.69e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.76e-06	1.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.76e-06	1.66e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.76e-06	1.66e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.71e-06	1.63e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.7e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	2.69e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.63e-06	1.58e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.61e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.61e-06	1.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.58e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	2.58e-06	1.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.48e-06	1.49e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.48e-06	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.47e-06	1.49e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.44e-06	1.47e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.43e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.41e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	2.4e-06	1.45e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	2.35e-06	1.41e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.32e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	2.3e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.27e-06	1.37e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.25e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.24e-06	1.35e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.23e-06	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.23e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.21e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.19e-06	1.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.17e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.13e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.12e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.12e-06	1.27e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.1e-06	1.26e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.98e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	1.87e-06	1.13e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.87e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.79e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.71e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.45e-06	8.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.38e-06	8.32e-06	CbGpPWpGaD
